Other News To Note
Wednesday, August 29, 2012
Bolder BioTechnology Inc., of Boulder, Colo., published a study showing that its long-acting inerleukin-11 analogue prevented kidney damage from ischemia reperfusion injury in mice. The research was carried out at Columbia University, and published online in the American Journal of Physiology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.